Logo image of AVBP

ARRIVENT BIOPHARMA INC (AVBP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AVBP - US04272N1028 - Common Stock

20.86 USD
-1.04 (-4.75%)
Last: 1/16/2026, 8:00:01 PM
20.86 USD
0 (0%)
After Hours: 1/16/2026, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, AVBP scores 3 out of 10 in our fundamental rating. AVBP was compared to 525 industry peers in the Biotechnology industry. AVBP has a great financial health rating, but its profitability evaluates not so good. AVBP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • AVBP had negative earnings in the past year.
  • AVBP had a negative operating cash flow in the past year.
AVBP Yearly Net Income VS EBIT VS OCF VS FCFAVBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • AVBP has a Return On Assets of -46.36%. This is comparable to the rest of the industry: AVBP outperforms 53.90% of its industry peers.
  • AVBP has a better Return On Equity (-49.64%) than 66.67% of its industry peers.
Industry RankSector Rank
ROA -46.36%
ROE -49.64%
ROIC N/A
ROA(3y)-30.66%
ROA(5y)N/A
ROE(3y)-32.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVBP Yearly ROA, ROE, ROICAVBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AVBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVBP Yearly Profit, Operating, Gross MarginsAVBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for AVBP has been increased compared to 1 year ago.
  • There is no outstanding debt for AVBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVBP Yearly Shares OutstandingAVBP Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
AVBP Yearly Total Debt VS Total AssetsAVBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • AVBP has an Altman-Z score of 21.84. This indicates that AVBP is financially healthy and has little risk of bankruptcy at the moment.
  • AVBP's Altman-Z score of 21.84 is amongst the best of the industry. AVBP outperforms 89.71% of its industry peers.
  • There is no outstanding debt for AVBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.84
ROIC/WACCN/A
WACCN/A
AVBP Yearly LT Debt VS Equity VS FCFAVBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 14.90 indicates that AVBP has no problem at all paying its short term obligations.
  • AVBP has a better Current ratio (14.90) than 91.81% of its industry peers.
  • A Quick Ratio of 14.90 indicates that AVBP has no problem at all paying its short term obligations.
  • AVBP has a better Quick ratio (14.90) than 91.81% of its industry peers.
Industry RankSector Rank
Current Ratio 14.9
Quick Ratio 14.9
AVBP Yearly Current Assets VS Current LiabilitesAVBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for AVBP have decreased strongly by -61.70% in the last year.
EPS 1Y (TTM)-61.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 19.01% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-72.25%
EPS Next 2Y-24.43%
EPS Next 3Y-4.6%
EPS Next 5Y19.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVBP Yearly Revenue VS EstimatesAVBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
AVBP Yearly EPS VS EstimatesAVBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • AVBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AVBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVBP Price Earnings VS Forward Price EarningsAVBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVBP Per share dataAVBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as AVBP's earnings are expected to decrease with -4.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.43%
EPS Next 3Y-4.6%

More info and screens

0

5. Dividend

5.1 Amount

  • AVBP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (1/16/2026, 8:00:01 PM)

After market: 20.86 0 (0%)

20.86

-1.04 (-4.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-01
Inst Owners90.76%
Inst Owner Change0.12%
Ins Owners3.13%
Ins Owner Change0%
Market Cap861.10M
Revenue(TTM)N/A
Net Income(TTM)-151.40M
Analysts86.32
Price Target41.57 (99.28%)
Short Float %18.26%
Short Ratio18.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.24%
Min EPS beat(2)-25.38%
Max EPS beat(2)-3.09%
EPS beat(4)1
Avg EPS beat(4)-46.49%
Min EPS beat(4)-180.53%
Max EPS beat(4)23.03%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.96%
PT rev (3m)5.03%
EPS NQ rev (1m)0.46%
EPS NQ rev (3m)-12.3%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-6.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.82
P/tB 2.82
EV/EBITDA N/A
EPS(TTM)-4.24
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.54
OCFYN/A
SpS0
BVpS7.39
TBVpS7.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.36%
ROE -49.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.66%
ROA(5y)N/A
ROE(3y)-32.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.9
Quick Ratio 14.9
Altman-Z 21.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.07%
EPS Next Y-72.25%
EPS Next 2Y-24.43%
EPS Next 3Y-4.6%
EPS Next 5Y19.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-73.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-57.4%
EBIT Next 3Y-16.07%
EBIT Next 5YN/A
FCF growth 1Y-157.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.11%
OCF growth 3YN/A
OCF growth 5YN/A

ARRIVENT BIOPHARMA INC / AVBP FAQ

Can you provide the ChartMill fundamental rating for ARRIVENT BIOPHARMA INC?

ChartMill assigns a fundamental rating of 3 / 10 to AVBP.


What is the valuation status of ARRIVENT BIOPHARMA INC (AVBP) stock?

ChartMill assigns a valuation rating of 0 / 10 to ARRIVENT BIOPHARMA INC (AVBP). This can be considered as Overvalued.


How profitable is ARRIVENT BIOPHARMA INC (AVBP) stock?

ARRIVENT BIOPHARMA INC (AVBP) has a profitability rating of 1 / 10.


How financially healthy is ARRIVENT BIOPHARMA INC?

The financial health rating of ARRIVENT BIOPHARMA INC (AVBP) is 8 / 10.